D Ehninger1, P J de Vries, A J Silva. 1. Departments of Neurobiology, Psychiatry & Biobehavioral Sciences, Psychology and the Brain Research Institute, UCLA, Los Angeles, CA 90095-1761, USA. dehninger@mednet.ucla.edu
Abstract
BACKGROUND: Tuberous sclerosis (TSC) is a multi-system disorder caused by heterozygous mutations in the TSC1 or TSC2 gene and is often associated with neuropsychiatric symptoms, including intellectual disability, specific neuropsychological deficits, autism, other behavioural disorders and epilepsy. METHOD: Here, we review evidence from animal models of TSC for the role of specific molecular and cellular processes in the pathogenesis of cognitive, developmental and epilepsy-related manifestations seen in the disorder. RESULTS: Recent evidence shows that, in animal models, disinhibited mTOR (mammalian target of rapamycin) signalling substantially contributes to neuropsychiatric phenotypes, including cognitive deficits and seizures. We discuss potential pathogenetic mechanisms involved in the cognitive phenotypes of TSC and present implications regarding mTOR inhibitor-based treatments for TSC-related neuropsychiatric features. CONCLUSIONS: Results suggest that reversing the underlying molecular deficits of TSC with rapamycin or other mTOR inhibitors could result in clinically significant improvements of cognitive function and neurological symptoms, even if treatments are started in adulthood.
BACKGROUND:Tuberous sclerosis (TSC) is a multi-system disorder caused by heterozygous mutations in the TSC1 or TSC2 gene and is often associated with neuropsychiatric symptoms, including intellectual disability, specific neuropsychological deficits, autism, other behavioural disorders and epilepsy. METHOD: Here, we review evidence from animal models of TSC for the role of specific molecular and cellular processes in the pathogenesis of cognitive, developmental and epilepsy-related manifestations seen in the disorder. RESULTS: Recent evidence shows that, in animal models, disinhibited mTOR (mammalian target of rapamycin) signalling substantially contributes to neuropsychiatric phenotypes, including cognitive deficits and seizures. We discuss potential pathogenetic mechanisms involved in the cognitive phenotypes of TSC and present implications regarding mTOR inhibitor-based treatments for TSC-related neuropsychiatric features. CONCLUSIONS: Results suggest that reversing the underlying molecular deficits of TSC with rapamycin or other mTOR inhibitors could result in clinically significant improvements of cognitive function and neurological symptoms, even if treatments are started in adulthood.
Authors: E Gratacós; C Ghelardini; L M Gherardini; N Galeotti; K J Murphy; A Bartolini; C M Regan Journal: Neuroreport Date: 1998-08-24 Impact factor: 1.837
Authors: M van Slegtenhorst; R de Hoogt; C Hermans; M Nellist; B Janssen; S Verhoef; D Lindhout; A van den Ouweland; D Halley; J Young; M Burley; S Jeremiah; K Woodward; J Nahmias; M Fox; R Ekong; J Osborne; J Wolfe; S Povey; R G Snell; J P Cheadle; A C Jones; M Tachataki; D Ravine; J R Sampson; M P Reeve; P Richardson; F Wilmer; C Munro; T L Hawkins; T Sepp; J B Ali; S Ward; A J Green; J R Yates; J Kwiatkowska; E P Henske; M P Short; J H Haines; S Jozwiak; D J Kwiatkowski Journal: Science Date: 1997-08-08 Impact factor: 47.728
Authors: N Meiri; C Ghelardini; G Tesco; N Galeotti; D Dahl; D Tomsic; S Cavallaro; A Quattrone; S Capaccioli; A Bartolini; D L Alkon Journal: Proc Natl Acad Sci U S A Date: 1997-04-29 Impact factor: 11.205
Authors: Katrin Düvel; Jessica L Yecies; Suchithra Menon; Pichai Raman; Alex I Lipovsky; Amanda L Souza; Ellen Triantafellow; Qicheng Ma; Regina Gorski; Stephen Cleaver; Matthew G Vander Heiden; Jeffrey P MacKeigan; Peter M Finan; Clary B Clish; Leon O Murphy; Brendan D Manning Journal: Mol Cell Date: 2010-07-30 Impact factor: 17.970
Authors: Charles A Hoeffer; Emanuela Santini; Tao Ma; Elizabeth C Arnold; Ashley M Whelan; Helen Wong; Philippe Pierre; Jerry Pelletier; Eric Klann Journal: J Neurophysiol Date: 2012-10-10 Impact factor: 2.714